A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

December 31, 2013

Conditions
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Interventions
DRUG

asparaginase Erwinia chrysanthemi

Trial Locations (22)

10032

Columbia Presbyterian Medical Center, New York

10467

Montifiore Medical Center, The Bronx

15224

Children's Hospital of Pittsburgh, Pittsburgh

21231

John Hopkins, Baltimore

22042

Inova Fairfax Medical Center, Falls Church

33701

All Children's Hospital, St. Petersburg

53226

Children's Hospital of Wisconsin, Milwaukee

55406

Children's Hospital and Clinics of Minnesota, Minneapolis

55455

University of Minnesota, Minneapolis

60611

Children's Memorial Hospital, Chicago

77030

Texas Children's Hospital, Houston

80045

Children's Hospital, Aurora

90027

Children's Hospital of Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange County

94304

Stanford Medical Center, Palo Alto

97239

Oregon Health & Sciences, Portland

02215

Dana Farber Cancer Institute, Boston

08903

UMDNJ/Robert Wood Johnson, New Brunswick

L8S4R1

McMasters University Medical Center, Hamilton

m561X8

Sick Children's Hospital, Toronto

H3T1CS

Hospital St. Justine, Saint Catherine

CIV462

Quebec Children's Hospital, Sainte-Foy

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY